🇺🇸 FDA
Pipeline program

DT-168

DTX-168-201

Phase 2 small_molecule active

Quick answer

DT-168 for Fuchs Endothelial Corneal Dystrophy is a Phase 2 program (small_molecule) at Design Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Design Therapeutics
Indication
Fuchs Endothelial Corneal Dystrophy
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials